188 related articles for article (PubMed ID: 24477421)
1. Single center experience with oxybutynin transdermal system (patch) for management of symptoms related to non-neuropathic overactive bladder in children: an attractive, well tolerated alternative form of administration.
Gleason JM; Daniels C; Williams K; Varghese A; Koyle MA; Bägli DJ; Pippi Salle JL; Lorenzo AJ
J Pediatr Urol; 2014 Aug; 10(4):753-7. PubMed ID: 24477421
[TBL] [Abstract][Full Text] [Related]
2. Transdermal oxybutynin for overactive bladder.
Davila GW; Starkman JS; Dmochowski RR
Urol Clin North Am; 2006 Nov; 33(4):455-63, viii. PubMed ID: 17011381
[TBL] [Abstract][Full Text] [Related]
3. Oxybutynin gel for the treatment of overactive bladder.
Gomelsky A; Dmochowski RR
Expert Opin Pharmacother; 2012 Jun; 13(9):1337-43. PubMed ID: 22607010
[TBL] [Abstract][Full Text] [Related]
4. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
Sand P; Zinner N; Newman D; Lucente V; Dmochowski R; Kelleher C; Dahl NV
BJU Int; 2007 Apr; 99(4):836-44. PubMed ID: 17187655
[TBL] [Abstract][Full Text] [Related]
5. Transdermal oxybutynin: sticking to the facts.
Cartwright R; Cardozo L
Eur Urol; 2007 Apr; 51(4):907-14; discussion 914. PubMed ID: 17157979
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters.
Humblet M; Verpoorten C; Christiaens MH; Hirche H; Jansen K; Buyse G; van Gool JD
Neurourol Urodyn; 2015 Apr; 34(4):336-42. PubMed ID: 24436114
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity.
Cartwright PC; Coplen DE; Kogan BA; Volinn W; Finan E; Hoel G
J Urol; 2009 Oct; 182(4):1548-54. PubMed ID: 19683731
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: A randomized double-blind trial.
Yamaguchi O; Uchida E; Higo N; Minami H; Kobayashi S; Sato H;
Int J Urol; 2014 Jun; 21(6):586-93. PubMed ID: 24350662
[TBL] [Abstract][Full Text] [Related]
9. Optimum Dose of Once-Daily Oxybutynin Patch in Japanese Patients with Overactive Bladder: A Randomized Double-Blind Trial Versus Placebo.
Yamaguchi O; Uchida E; Higo N; Minami H; Kobayashi S; Sato H;
Low Urin Tract Symptoms; 2016 Sep; 8(3):150-8. PubMed ID: 27619779
[TBL] [Abstract][Full Text] [Related]
10. Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder.
Staskin DR; Robinson D
Expert Opin Pharmacother; 2009 Dec; 10(18):3103-11. PubMed ID: 19954278
[TBL] [Abstract][Full Text] [Related]
11. Transdermally-delivered oxybutynin (Oxytrol(R) for overactive bladder.
Ho C
Issues Emerg Health Technol; 2001 Oct; (24):1-4. PubMed ID: 11776281
[TBL] [Abstract][Full Text] [Related]
12. Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence.
Cartwright R; Srikrishna S; Cardozo L; Robinson D
BJU Int; 2011 Jan; 107(1):70-6. PubMed ID: 20626389
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
Kennelly MJ; Lemack GE; Foote JE; Trop CS
Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264
[TBL] [Abstract][Full Text] [Related]
14. Transdermal drug delivery treatment for overactive bladder.
Dmochowski RR; Starkman JS; Davila GW
Int Braz J Urol; 2006; 32(5):513-20. PubMed ID: 17081319
[TBL] [Abstract][Full Text] [Related]
15. Evolution of transdermal oxybutynin in the treatment of overactive bladder.
Sahai A; Mallina R; Dowson C; Larner T; Khan MS
Int J Clin Pract; 2008 Jan; 62(1):167-70. PubMed ID: 18173821
[TBL] [Abstract][Full Text] [Related]
16. Prescription pattern of oxybutynin ER in patients with overactive bladder in real life practice: a multicentre, open-label, prospective observational study.
Yoo DS; Han JY; Lee KS; Choo MS
Int J Clin Pract; 2012 Feb; 66(2):132-8. PubMed ID: 22188444
[TBL] [Abstract][Full Text] [Related]
17. [Maintenance of the efficacy of the oxybutynin patch for the treatment of overactive bladder syndrome despite the change in the area of application: study of four cases.].
Merino Salas S
Arch Esp Urol; 2018 Jun; 71(5):502-505. PubMed ID: 29889041
[TBL] [Abstract][Full Text] [Related]
18. Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.
Herschorn S; Stothers L; Carlson K; Egerdie B; Gajewski JB; Pommerville P; Schulz J; Radomski S; Drutz H; Barkin J; Paradiso-Hardy F
J Urol; 2010 May; 183(5):1892-8. PubMed ID: 20303119
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome.
Sand PK; Davila GW; Lucente VR; Thomas H; Caramelli KE; Hoel G
Am J Obstet Gynecol; 2012 Feb; 206(2):168.e1-6. PubMed ID: 21963104
[TBL] [Abstract][Full Text] [Related]
20. Cognitive function assessment in elderly patients with overactive bladder treated with transdermal oxybutynin.
Müller-Arteaga C; Batista-Miranda JE; Zubiaur Libano C; El Khoury Moreno R; Morales Solchaga G; Casas Nebra J; Leva Vallejo M; Gonzalez Garcia O; Errando-Smet C; Arlandis-Guzman S
Actas Urol Esp (Engl Ed); 2019 Apr; 43(3):143-150. PubMed ID: 30470585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]